GlaxoSmithKlineGlaxoSmithKline Corporate and Social Responsibility Report 2002
Reporting Front PageDownloads
CSR 2002 home
A global challenge
The scope of our business
Our contribution to society
Medicines for the developing world
Community investment
Research & development
Valuing people
Environment, health and safety
Business ethics and integrity
Management of CSR
Web references
Corporate Social Responsibility Committee
Management of CSR
Previous
Next
   
 

Contributing to improving people's lives as a responsible corporate citizen is an integral and established part of our business practice.

Our corporate and social responsibility (CSR) activities, including those covered in this report, are managed in the most appropriate functions in the organisation rather than through a central department. We believe this is the most effective approach to managing the issues because they remain an integrated part of the everyday operation of the business.

To facilitate policy development, implementation and communication, a cross-functional team was established at the beginning of 2002 to ensure a comprehensive and co-ordinated approach. The team is made up of representatives from the key business areas who ensure that policies are in place and mechanisms exist for their implementation and monitoring. The representatives also contribute to reporting progress through this report and in other ways, for example through conference presentations and on our website.

During the year this cross-functional team developed indicators that will support reporting on key issues. In determining the indicators, we aim to strike a balance between the desires of our stakeholders for greater transparency about our operations with the realities and costs of running the business.

We also believe that stakeholder discussion on anything that requires specialist knowledge is best undertaken by those with such expertise. Hence the team representatives discuss issues directly with those who have expressed an interest or concern, and central co-ordination means that broader issues are brought to the attention of the cross-functional team.

GSK has a process in place for identifying, evaluating and managing significant business risks, and this includes reputational and corporate responsibility issues. Our risk management process accords with the Turnbull guidance and our formal risk assessment is updated at least once a year. The Risk Oversight and Compliance Council coordinates internal control and risk management activities to ensure effective management of significant risks.

During the year, the CSR committee of Non-Executive Board members gave advice on how we report our activities, and had specific input into our approach to community investment, environment, health and safety and human resources policies including diversity and human rights issues.

Diagram: Cross-Functional Management of CSR Activities

Previous
Next


Top


CSR 2002 Home | Reporting Front Page | Downloads | Main Site

 
Updated March 28, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement